ELMD Electromed Inc

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 11, 2025

 

ELECTROMED, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Minnesota	001-34839	41-1732920
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

 

500 Sixth Avenue NW

New Prague, MN 56071 

(Address of Principal Executive Offices) (Zip Code)

 

(952) 758-9299

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Common Stock, $0.01 par value		ELMD		NYSE American LLC
(Title of each class)		(Trading Symbol)		(Name of each exchange on which registered)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02

Results of Operations and Financial Condition.

 

On February 11, 2025, Electromed, Inc., a Minnesota corporation (the “Company”), issued a press release announcing its financial results for the second quarter ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference into this Item 2.02.

 

Item 7.01

Regulation FD Disclosure.

 

The Company has updated its investor presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference into this Item 7.01. The Company intends to use the presentation in whole or in part, in one or more meetings with investors and analysts.

 

Item 9.01

Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit Number		Description
99.1		Press Release dated February 11, 2025
99.2		Company Investor Presentation dated February 11, 2025
104		Cover Page Interactive Data File (embedded in the cover page and formatted in inline XBRL)

 

The information contained in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	ELECTROMED, INC.
Date: February 11, 2025	By:	/s/ Bradley M. Nagel
	Name:	Bradley M. Nagel
	Title:	Chief Financial Officer

 

 

Exhibit 99.1

 

Electromed, Inc. Announces Record Financial Performance in Fiscal 2025 Second Quarter

 

Company maintained strong momentum to deliver another quarter of record revenue and earnings, while continuing to invest in multiple strategic growth initiatives

 

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and six months ended December 31, 2024 (“Q2 FY 2025”).

 

Q2 FY 2025 Company Highlights

 

●

Net revenue increased 18.7% to a record $16.3 million in Q2 FY 2025, from $13.7 million in the second quarter of the prior fiscal year.

●

Operating income increased to a record $2.5 million, 15.6% of net revenues and a year-over-year increase of 12.3%.

●

Net income was $2.0 million, or $0.22 per diluted share, compared to $1.7 million, or $0.19 per diluted share in Q2 FY 2024.

●

Continued to deliberately expand the sales force, ending the quarter with 54 reps.

●

Reached over 10,000 clinicians through the “Triple Down on Bronchiectasis” educational campaign launched in Q1 FY 2025.

 

“Our team’s performance across the board in sales, marketing, manufacturing, and order fulfillment was outstanding,” said Jim Cunniff, President, and Chief Executive Officer. “The impact of their work is plain to see, with strong growth in all three of our customer categories, record quarterly revenues and solid operating and net income during the quarter. A prime example of our sterling performance is our ability to improve our working capital by reducing inventory while continuing to meet our patients’ therapy needs. This is particularly important for us given our unique direct-to-patient model. We are also continually seeking ways to improve efficiency across the organization, and during the quarter we initiated an investment in a new CRM system to further enhance our commercial team’s productivity. I am proud of Electromed’s position as a growing and profitable MedTech company, and we expect to report continued improvements throughout the remainder of fiscal 2025.”

 

Q2 FY 2025 Results

 

All amounts below are for the three months ended December 31, 2024, and compare to the three months ended December 31, 2023 (“Q2 FY 2024”).

 

Net revenues grew 18.7% to $16.3 million, from $13.7 million.

 

Revenue in our direct homecare business increased year-over-year by 15.2% to $14.6 million, from $12.7 million. The increase in revenue was due to an increase in referrals and approvals driven by an increase in direct sales representatives, higher net revenues per approval, and efficiencies within our reimbursement department. Field sales force employees totaled 60 at quarter end, 54 of which were direct sales representatives. The annualized homecare revenue per weighted average direct sales representative in Q2 was $1,077,000, slightly higher than Electromed’s target range of $900,000 to $1,000,000.

 

Gross profit increased to $12.6 million or 77.7% of net revenues from $10.5 million or 77.0% of net revenues. The increase in gross profit dollars and percentage were primarily a result of increased volumes and higher average net revenue per device.

 

 

Selling, general and administrative (“SG&A”) expenses were $9.8 million representing an increase of $1.7 million or 20.3%. The increase in the current year period was primarily due to the accelerated recognition of non-cash share-based compensation associated with the vesting of performance-based equity awards, along with increased salaries and incentive compensation related to the higher average number of sales, sales support, marketing, and reimbursement personnel to process higher patient referrals.

 

Operating income was a record $2.5 million, compared to $2.3 million. The increase in operating income was driven primarily by increased revenue and gross profit.

 

Net income was a record $2.0 million, or $0.22 per diluted share, compared to $1.7 million, or $0.19 per diluted share.

 

As of December 31, 2024, Electromed had $16.2 million in cash, $22.8 million in accounts receivable and no debt, achieving a working capital of $35.5 million and total shareholders’ equity of $43.6 million. The cash balance reflects an increase of $0.2 million for the six months ended December 31, 2024, compared to an increase in cash of $3.1 million in the six months ended December 31, 2023. The increase in cash for the 6 months ended December 31, 2024, was driven by $5.5 million of positive operating cash flow, offset by share repurchases of approximately $4.5 million of Electromed common stock and $0.8 million of taxes paid from net share settlement of vested stock.

 

Conference Call and Webcast Information

 

The conference call with members of Electromed management will be held at 5:00 p.m. Eastern Time on Tuesday, February 11, 2025.

 

Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International) using passcode 0177798.

 

The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1705037&tp_key=8af23b601f.

 

For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 10196088. Additionally, an online replay will be available for one year in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx

 

About Electromed, Inc.

 

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

 

 

Cautionary Statements

 

Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “plan” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to, competitive nature of our market; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual property portfolio; the risks associated with expansion into international markets, as well as other factors we may describe from time to time in the Company’s reports filed with the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

 

Brad Nagel, Chief Financial Officer
(952) 758-9299
investorrelations@electromed.com

 

Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641
mike.cavanaugh@icrhealthcare.com

 

Source: Electromed, Inc.

 

 

Electromed, Inc.

 

Condensed Balance Sheets

 

		December 31, 2024				June 30, 2024
		(Unaudited)				(Audited)
Assets
Current Assets
Cash and cash equivalents		$	16,235,000			$	16,080,000
Accounts receivable (net of allowances for credit losses of $45,000)			22,775,000				23,333,000
Contract assets			997,000				719,000
Inventories			3,081,000				3,712,000
Income taxes receivable			514,000				-
Prepaid expenses and other current assets			587,000				329,000
Total current assets			44,189,000				44,173,000
Property and equipment, net			5,216,000				5,165,000
Finite-life intangible assets, net			609,000				657,000
Other assets			108,000				87,000
Deferred income taxes			2,152,000				2,152,000
Total assets		$	52,274,000			$	52,234,000
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable			1,506,000				1,010,000
Accrued compensation			3,623,000				3,893,000
Income tax payable			-				277,000
Warranty reserve			1,599,000				1,567,000
Other accrued liabilities			1,939,000				930,000
Total current liabilities			8,667,000				7,677,000
Other long-term liabilities			4,000				12,000
Total liabilities			8,671,000				7,689,000
Commitments and Contingencies
Shareholders’ Equity
Common stock, $0.01 par value per share, 13,000,000 shares authorized;
8,556,844 and 8,637,883 shares issued and outstanding, as of December 31, 2024 and June 30, 2024, respectively			86,000				87,000
Additional paid-in capital			20,940,000				20,790,000
Retained earnings			22,577,000				23,668,000
Total shareholders’ equity			43,603,000				44,545,000
Total liabilities and shareholders’ equity		$	52,274,000			$	52,234,000

 

 

Electromed, Inc.

 

Condensed Statements of Operations

		Three Months Ended								Six Months Ended
		December 31,								December 31,
		2024				2023				2024				2023
			(Unaudited)				(Unaudited)				(Unaudited)				(Unaudited)
Net revenues		$	16,255,000			$	13,689,000			$	30,923,000			$	26,013,000
Cost of revenues			3,628,000				3,144,000				6,805,000				5,970,000
Gross profit			12,627,000				10,545,000				24,118,000				20,043,000
Operating expenses
Selling, general and administrative			9,834,000				8,175,000				19,221,000				17,325,000
Research and development			251,000				107,000				417,000				313,000
Total operating expenses			10,085,000				8,282,000				19,638,000				17,638,000
Operating income			2,542,000				2,263,000				4,480,000				2,405,000
Interest income, net			152,000				96,000				347,000				173,000
Net income before income taxes			2,694,000				2,359,000				4,827,000				2,578,000
Income tax expense			726,000				685,000				1,385,000				749,000
Net income		$	1,968,000			$	1,674,000			$	3,442,000			$	1,829,000
Income per share:
Basic		$	0.23			$	0.20			$	0.41			$	0.21
Diluted		$	0.22			$	0.19			$	0.38			$	0.21
Weighted-average common shares outstanding:
Basic			8,424,534				8,545,120				8,494,511				8,541,254
Diluted			8,953,349				8,800,172				8,983,726				8,791,519

 

 

Electromed, Inc.

 

Condensed Statements of Cash Flows

 

		Six Months Ended December 31,
		2024				2023
		(Unaudited)				(Unaudited)
Cash Flows From Operating Activities
Net income		$	3,442,000			$	1,829,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation			414,000				398,000
Amortization of finite-life intangible assets			78,000				25,000
Share-based compensation expense			1,652,000				791,000
Changes in operating assets and liabilities:
Accounts receivable			558,000				1,142,000
Contract assets			(278,000	)			(87,000	)
Inventories			500,000				(509,000	)
Prepaid expenses and other assets			(279,000	)			1,104,000
Income taxes receivable, net			(791,000	)			(83,000	)
Accounts payable and accrued liabilities			434,000				(1,171,000	)
Accrued compensation			(270,000	)			(212,000	)
Net cash provided by operating activities			5,460,000				3,227,000
Cash Flows From Investing Activities
Expenditures for property and equipment			(270,000	)			(180,000	)
Expenditures for finite-life intangible assets			(25,000	)			(40,000	)
Net cash used for investing activities			(295,000	)			(220,000	)
Cash Flows From Financing Activities
Issuance of common stock upon exercise of options			346,000				55,000
Taxes paid on net share settlement of stock awards			(820,000	)			-
Repurchase of common stock			(4,536,000	)			-
Net cash (used for) provided by financing activities			(5,010,000	)			55,000
Net increase in cash			155,000				3,062,000
Cash And Cash Equivalents
Beginning of period			16,080,000				7,372,000
End of period		$	16,235,000			$	10,434,000

 

 

Exhibit 99.2

 

| 1 Investor Presentation Electromed, Inc. Investor Presentation February 11, 2025 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies

| 2 Investor Presentation Forward Looking Statements Certain statements in this press release constitute forward - looking statements as defined in the US Private Securities Litigation Reform Act of 1995 . Forward - looking statements can generally be identified by words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements . Forward - looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements . Examples of risks and uncertainties for the Company include, but are not limited to the competitive nature of our market ; changes to Medicare, Medicaid, or private insurance reimbursement policies ; changes to state and federal health care laws ; changes affecting the medical device industry ; our ability to develop new sales channels for our products such as the homecare distributor channel ; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances ; new drug or pharmaceutical discoveries ; general economic and business conditions ; our ability to renew our line of credit or obtain additional credit as necessary ; our ability to protect and expand our intellectual property portfolio ; the risks associated with expansion into international markets, as well as other factors we may describe from time to time in the Company’s reports filed with the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10 - K, as amended from time to time, and subsequent Quarterly Reports on Form 10 - Q and Current Reports on Form 8 - K) . Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions . Shareholders and other readers should not place undue reliance on “forward - looking statements,” as such statements speak only as of the date of this press release . We undertake no obligation to update them in light of new information or future events .

| 3 Investor Presentation Electromed – Who We Are Electromed, Inc. is a growing medical device company focused on airway management to help people around the world breathe better, stay healthier, and lead active and fulfilling lives. As of and for 12 months ended 9/30/2024 Key Stats : Headquarters: New Prague, MN Ticker: ELMD Established: 1992 Annual Revenue: $59.7M Market Cap: $250M Share Count: 8.5M 174 Employees Manufacturing in Minnesota HFCWO Market Focus

| 4 Investor Presentation Electromed Highlights » Growing and profitable medical technology company » A leader in the large and expanding airway clearance market » The SmartVest ® Airway Clearance System’s H igh F requency C hest W all Oscillation (“HFCWO”) technology supported by clinical outcomes data with strong reimbursement. » Attractive direct - to - patient and provider model » Strong financial profile with attractive gross margins and well - capitalized balance sheet $35.8 $41.7 $48.1 $54.7 $59.7 $2.4 $2.3 $3.2 $5.2 $6.8 FY'21 FY'22 FY'23 FY'24 TTM 12/31/2024 Revenue Net Income 29% Net Income CAGR* *FY ‘21 through FY ‘24

| 5 Investor Presentation What is Bronchiectasis (BE)? » Irreversible lung condition characterized by abnormal widening of one or more of the bronchi (airways) » Repeated episodes of pulmonary inflammation and infection leads to mucus accumulating in the airways » Mean prevalence of bronchiectasis in patients with COPD is 54%¹ 1.Chalmers J. and Sethi S. Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategi es in adults. NPJ Prim Care Respir Med . 2017;27:18 HFCWO Under - prescribed Disease Underdiagnosed Disease Misdiagnosed

| 6 Investor Presentation U.S. Market: Large, Growing, Underpenetrated 1. Derived from GUIDEHOUSE 2023 NASM claims database 2. Derived from GUIDEHOUSE 2023 literature review and 2023 CDC NHANES data Bronchiectasis HFCWO penetration ~15% 1 Diagnosed BE population growing at ~12% annually 1 Estimated Net Bronchiectasis prevalence, DIAGNOSED 1 Estimated bronchiectasis prevalence, UNDIAGNOSED with COPD/BE overla p 2 Estimated HFCWO bronchiectasis penetration, treated population 1 ~824K U.S. BE Diagnosed 1 4.1 million U.S. Undiagnosed 2 ~127K HFCWO ADOPTED 1

| 7 Investor Presentation How is Bronchiectasis Treated? Antibiotics, Anti - Inflammatories, Airway Clearance

| 8 Investor Presentation How is Bronchiectasis Treated? HFCWO Therapy – Mimics Manual CPT

| 9 Investor Presentation Sleek and light weight generator Intuitive user interface for better patient adherence More portable and easier for travel SmartVest Clearway ® HFCWO Designed with the Patient in Mind An Enhanced Patient Experience SmartVest ® has a well - established reimbursement code from CMS – E0483; Electromed has over 275M contracted lives in the US

| 10 Investor Presentation SmartNotes™ Patient Progress Report SmartNotes combine patient Quality of Life and Therapy Utilization data to provide physicians with extended views into disease management » TeleRespiratory Services : A team of Respiratory Therapists stay connected with patients and support their therapy utilization. » Outcomes Management : Easy - to - read report provides physicians with a comprehensive view of disease progression and therapy impact. Patient Outcomes and Treatment Progress to Physicians

| 11 Investor Presentation Clinical Evidence Electromed has Published Studies Showing Effectiveness of HFCWO to Treat Bronchiectasis 1.Sievert CE, et al 2016. Using High Frequency Chest Wall Oscillation in a Bronchiectasis Patient Population: An Outcomes - Based Case Review. Respiratory Therapy, 11(4), 34 - 38. 2. Sievert CE, et al 2018. Incidence of Bronchiectasis - Related Exacerbation Rates After HFCWO Treatment — A Longitudinal Outcome - B ased Study, Respiratory Therapy, 13(2), 38 - 41. 57 % Reduction in antibiotic prescriptions 1 59 % Decrease in hospitalizations 1 75 % Fewer emergency department visits 2 Therapy with SmartVest® significantly decreased exacerbations requiring hospitalization, antibiotic use, and stabilizes lung function. Powner (2018) Therapy with HFCWO demonstrated key health outcomes improved in post - compared to pre - index period: cough, all - cause hospitalizations, pneumonia, and pulmonary hospitalizations. DeKoven (2022)

| 12 Investor Presentation Direct - to - Patient Model Drives Attractive Margin Profile Manufacturer DME Patient $ $ vs. Electromed Patient $$ Traditional Medical Equipment Channel Direct - to - Patient Distribution (Electromed) ELMD expects gross margins in the mid - 70s and improving with the SmartVest ® Clearway ®

| 13 Investor Presentation Net Revenue Breakdown - $59.7M (TTM ended 12/31/2024) 1% [PE RCE NTA GE] 94% By Setting Homecare By Payer Homecare Qualified Referral Volume 73% 3% 22% 2% 47% 51% 2% Home Care 1 Hospitals Other Medicare Commercial/Other 2 Medicaid Bronchiectasis Cystic Fibrosis Neuromuscular Other 1.Includes $2.4 million from home care distributor revenue 2.Includes Managed Medicare and Managed Medicaid

| 14 Investor Presentation Growth Strategy How will Electromed Increase Market Share? Continued sales force expansion along with complementary infrastructure investments Increase brand awareness and revenue with direct - to - consumer and physician marketing Market development to improve diagnosis rates and evidence to support the adoption of the SmartVest system for patients SmartAdvantage ™ best - in - class customer care and support Expand e - prescribing capability

| 15 Investor Presentation Long - Term Objectives Electromed is committed to delivering long - term profitable growth Double - digit Revenue Growth Operating Margin Improvement Increase market share Deeper penetration of current SmartVest prescribers Operating leverage as revenue increases

| 16 Investor Presentation Why Invest? Large, expanding chronic lung diseases market Clinically proven technology Broad payor coverage Consistent double - digit organic revenue growth High gross margins , robust cash flow and expanding operating leverage

| 17 Investor Presentation Management Incentives Aligned w/Investors CEO Incentive Management’s Incentive Compensation Reward based on increasing total shareholder return . Focused solely on delivering financial results .

| 18 Investor Presentation Attractive Valuation (TTM and as of 12/31/2024 Results) Metric ELMD RUS ME Sales Growth 15.5% > 2.5% Gross Margin 76.8% > 55.6% Operating Margin 14.5% > (1.3%)

| 19 Investor Presentation Mike Cavanaugh ( 617) 877 - 8641 m ike.cavanaugh@westwicke.com Maren Czura (332) 242 - 4365 maren.czura@westwicke.com Jim Cunniff , President & CEO (952) 758 - 9299 jcunniff @Electromed.com Brad Nagel, CFO (952) 758 - 9299 bnagel@Electromed.com

| 20 Investor Presentation APPENDIX

| 21 Investor Presentation Financial Highlights Financial Summary Three months ended Year Ended ( in $ millions, except shares amounts) Dec 31, 2023 (unaudited) Dec 31, 2024 (unaudited) June 30, 2023 June 30, 2024 TTM Dec 31, 2024 (unaudited) Revenues $13.7 $16.3 $48.1 $54.7 $59.7 Gross Profit $10.5 $12.6 $36.5 $41.7 $45.8 Gross margin 77% 78% 76% 76% 77% Operating income $2.3 $2.5 $4.0 $6.6 $8.7 Operating margin 17% 16% 8% 12% 15% Net income $1.7 $2.0 $3.2 $5.2 $6.8 Diluted EPS $0.19 $0.22 $0.36 $0.58 $0.76 Diluted Shares 8,800,172 8,953,349 8,700,833 8,864,585 8,953,349 Cash provided by operations $3.5 $3.2 $1.3 $9.1 $11.3

v3.25.0.1

Cover	Feb. 11, 2025
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Feb. 11, 2025
Entity File Number	001-34839
Entity Registrant Name	ELECTROMED, INC.
Entity Central Index Key	0001488917
Entity Tax Identification Number	41-1732920
Entity Incorporation, State or Country Code	MN
Entity Address, Address Line One	500 Sixth Avenue NW
Entity Address, City or Town	New Prague
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	56071
City Area Code	(952)
Local Phone Number	758-9299
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ELMD
Security Exchange Name	NYSEAMER
Entity Emerging Growth Company	false
Entity Information, Former Legal or Registered Name	Not Applicable

---